Observational study of patients with chronic hepatitis B infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Target PharmaSolutions, Inc. · NCT03692897
This study looks at how people with chronic hepatitis B are doing in real life after receiving different treatments to help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Target PharmaSolutions, Inc. (industry) |
| Locations | 31 sites (Phoenix, Arizona and 30 other locations) |
| Trial ID | NCT03692897 on ClinicalTrials.gov |
What this trial studies
The TARGET-HBV study is an observational research initiative that reviews outcomes for patients with chronic hepatitis B (CHB) infection. It focuses on collecting and analyzing real-world data from patients treated in both academic and community medical centers across the US and Canada. The study aims to address critical clinical questions regarding the management of CHB by creating a comprehensive database that reflects the natural history and health outcomes associated with antiviral treatments used in clinical practice.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are being managed for chronic hepatitis B, including those who have achieved a functional cure.
Not a fit: Patients with a known history of HIV or those who have undergone liver transplantation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the management and treatment outcomes of chronic hepatitis B, potentially improving patient care.
How similar studies have performed: Other observational studies in chronic hepatitis B management have shown success in providing valuable data, making this approach both relevant and tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion 1. Male or female patients, age ≥18 years 2. Being managed for chronic hepatitis B (CHB), including patients who have achieved functional cure and patients with concurrent delta hepatitis Exclusion 1. Inability to provide written informed consent 2. Known history of Human Immunodeficiency Virus (HIV) 3. History of liver transplantation
Where this trial is running
Phoenix, Arizona and 30 other locations
- Banner University Medical Center Phoenix — Phoenix, Arizona, United States (TERMINATED)
- Asian Pacific Liver Center at Coalition of Inclusive Medicine — Los Angeles, California, United States (ACTIVE_NOT_RECRUITING)
- California Liver Research Institute — Pasadena, California, United States (TERMINATED)
- Stanford University — Redwood City, California, United States (ACTIVE_NOT_RECRUITING)
- UC Davis GI/Hepatology Clinical Trials Unit — Sacramento, California, United States (TERMINATED)
- Silicon Valley Research Institute — San Jose, California, United States (TERMINATED)
- Yale University Digestive Diseases — New Haven, Connecticut, United States (TERMINATED)
- Medstar Georgetown University Hospital — Washington, District of Columbia, United States (TERMINATED)
- University of Florida — Gainesville, Florida, United States (TERMINATED)
- University of Miami, Schiff Center for Liver Disease — Miami, Florida, United States (TERMINATED)
- Consultative Gastroenterology — Atlanta, Georgia, United States (TERMINATED)
- Atlanta Gastroenterology — Atlanta, Georgia, United States (TERMINATED)
- Rush Universtiy Medical Center — Chicago, Illinois, United States (TERMINATED)
- University of Chicago — Chicago, Illinois, United States (TERMINATED)
- Mercy Medical Center — Baltimore, Maryland, United States (TERMINATED)
- University of Michigan — Ann Arbor, Michigan, United States (RECRUITING)
- Minnesota Gastroenterology, P.A. — Plymouth, Minnesota, United States (TERMINATED)
- Rutgers, Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States (TERMINATED)
- Dreamwork Medical, PLLC — Flushing, New York, United States (TERMINATED)
- Northwell Health Center for Liver Diseases and Transplantation — Manhasset, New York, United States (TERMINATED)
- NYU Langone Health — New York, New York, United States (TERMINATED)
- Weill Cornell Medical College — New York, New York, United States (TERMINATED)
- Columbia University Medical Center — New York, New York, United States (TERMINATED)
- UNC Liver Center — Chapel Hill, North Carolina, United States (TERMINATED)
- UT Southwestern Medical Center — Dallas, Texas, United States (TERMINATED)
- Digestive and Liver Disease Specialist — Norfolk, Virginia, United States (TERMINATED)
- Bon Secours Liver Institute of Richmond — Richmond, Virginia, United States (TERMINATED)
- Virginia Commonwealth University — Richmond, Virginia, United States (TERMINATED)
- Swedish Organ Transplant and Liver Center — Seattle, Washington, United States (TERMINATED)
- University of Washington/Harborview Medical Center — Seattle, Washington, United States (TERMINATED)
- UHN Toronto General Hospital — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Study coordinator: Stephanie Harrison
- Email: sharrison@targetrwe.com
- Phone: 919-930-2792
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatitis B, Hepatitis, Liver Diseases